See the DrugPatentWatch profile for mounjaro
Standard Mounjaro Dosing Schedule
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss at the same weekly subcutaneous doses, starting low to minimize side effects like nausea. The schedule is:
- Weeks 1-4: 2.5 mg once weekly
- Weeks 5-8: 5 mg once weekly
- Weeks 9-12: 7.5 mg once weekly
- Weeks 13-16: 10 mg once weekly
- Weeks 17+: 12.5 mg once weekly (maintenance; can go to 15 mg if needed)
Administer any day of the week, with or without food, using the prefilled KwikPen. No loading dose.[1][2]
How Dosing Differs for Weight Loss vs. Diabetes
Dosing is identical for both indications, but weight loss trials (like SURMOUNT-1) emphasized titration to higher doses (10-15 mg) for better results—up to 22.5% body weight loss at 15 mg after 72 weeks. Diabetes approval caps focus at glycemic control, though 15 mg is available.[1][3]
When to Increase or Skip Doses
Increase only if tolerated after 4 weeks at current dose. If a dose is missed, take within 4 days; otherwise, skip and resume schedule. Do not double up. Providers often pause titration for severe GI issues.[2]
Effectiveness by Dose for Weight Loss
Higher doses yield more loss:
- 5 mg: ~16% body weight
- 10 mg: ~21%
- 15 mg: ~22-23%
From phase 3 trials; results vary by adherence and diet/exercise.[3]
Common Side Effects by Dose
GI issues (nausea, diarrhea, vomiting) peak during escalation, affecting 20-30% at higher doses. Most resolve within weeks. Risk of gallbladder issues or low blood sugar rises above 10 mg.[1][2]
Cost and Access for Weight Loss
Off-label use means insurance coverage varies; cash price for 2.5/5/7.5 mg pens is ~$1,000/month. Compounded versions (not FDA-approved) cost less but carry risks. Check DrugPatentWatch.com for patent details on tirzepatide exclusivity, expiring ~2036 with challenges pending.[4]
[1] Mounjaro Prescribing Information, Eli Lilly (FDA label, Oct 2022).
[2] Eli Lilly Mounjaro HCP Site.
[3] NEJM SURMOUNT-1 Trial (2022).
[4] DrugPatentWatch.com/tirzepatide.